Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EBT (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed EBT for 6 consecutive years, with -$23.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 33.82% to -$23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$121.7 million, a 3.72% increase, with the full-year FY2025 number at -$129.8 million, down 2.66% from a year prior.
  • EBT was -$23.0 million for Q4 2025 at TScan Therapeutics, up from -$34.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$7.9 million in Q1 2021 to a low of -$34.7 million in Q4 2024.
  • A 5-year average of -$21.5 million and a median of -$21.1 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 120.91% in 2021, then surged 33.82% in 2025.
  • TScan Therapeutics' EBT stood at -$14.2 million in 2021, then crashed by 31.85% to -$18.7 million in 2022, then decreased by 4.75% to -$19.6 million in 2023, then plummeted by 77.02% to -$34.7 million in 2024, then soared by 33.82% to -$23.0 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's EBT are -$23.0 million (Q4 2025), -$34.1 million (Q1 2025), and -$34.7 million (Q4 2024).